These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
24. An Optimized Full-Length FLT3/CD3 Bispecific Antibody Demonstrates Potent Anti-leukemia Activity and Reversible Hematological Toxicity. Yeung YA; Krishnamoorthy V; Dettling D; Sommer C; Poulsen K; Ni I; Pham A; Chen W; Liao-Chan S; Lindquist K; Chin SM; Chunyk AG; Hu W; Sasu B; Chaparro-Riggers J; Djuretic I Mol Ther; 2020 Mar; 28(3):889-900. PubMed ID: 31981494 [TBL] [Abstract][Full Text] [Related]
25. A novel nonradioactive CFDA assay to monitor the cellular immune response in myeloid leukemia. Yang T; Chen ZZ; Kolb HJ; Buhmann R Immunobiology; 2013 Apr; 218(4):548-53. PubMed ID: 22883564 [TBL] [Abstract][Full Text] [Related]
26. Co-Stimulatory Bispecific Antibodies Induce Enhanced T Cell Activation and Tumor Cell Killing in Breast Cancer Models. Warwas KM; Meyer M; Gonçalves M; Moldenhauer G; Bulbuc N; Knabe S; Luckner-Minden C; Ziegelmeier C; Heussel CP; Zörnig I; Jäger D; Momburg F Front Immunol; 2021; 12():719116. PubMed ID: 34484225 [TBL] [Abstract][Full Text] [Related]
27. Targeting of folate receptor β on acute myeloid leukemia blasts with chimeric antigen receptor-expressing T cells. Lynn RC; Poussin M; Kalota A; Feng Y; Low PS; Dimitrov DS; Powell DJ Blood; 2015 May; 125(22):3466-76. PubMed ID: 25887778 [TBL] [Abstract][Full Text] [Related]
28. TRAIL expression by activated human CD4(+)V alpha 24NKT cells induces in vitro and in vivo apoptosis of human acute myeloid leukemia cells. Nieda M; Nicol A; Koezuka Y; Kikuchi A; Lapteva N; Tanaka Y; Tokunaga K; Suzuki K; Kayagaki N; Yagita H; Hirai H; Juji T Blood; 2001 Apr; 97(7):2067-74. PubMed ID: 11264173 [TBL] [Abstract][Full Text] [Related]
29. A trispecific killer engager molecule against CLEC12A effectively induces NK-cell mediated killing of AML cells. Arvindam US; van Hauten PMM; Schirm D; Schaap N; Hobo W; Blazar BR; Vallera DA; Dolstra H; Felices M; Miller JS Leukemia; 2021 Jun; 35(6):1586-1596. PubMed ID: 33097838 [TBL] [Abstract][Full Text] [Related]
30. AntiCD3Fv fused to human interleukin-3 deletion variant redirected T cells against human acute myeloid leukemic stem cells. Fan D; Li Z; Zhang X; Yang Y; Yuan X; Zhang X; Yang M; Zhang Y; Xiong D J Hematol Oncol; 2015 Feb; 8():18. PubMed ID: 25879549 [TBL] [Abstract][Full Text] [Related]
31. Development of A Chimeric Antigen Receptor Targeting C-Type Lectin-Like Molecule-1 for Human Acute Myeloid Leukemia. Laborda E; Mazagova M; Shao S; Wang X; Quirino H; Woods AK; Hampton EN; Rodgers DT; Kim CH; Schultz PG; Young TS Int J Mol Sci; 2017 Oct; 18(11):. PubMed ID: 29077054 [TBL] [Abstract][Full Text] [Related]
32. Generation of T-cell lines to autologous acute myeloid leukemia cells by competitive limiting dilution culture of acute myeloid leukemia mononuclear cells. Zhong RK; Lane TA; Ball ED Exp Hematol; 2008 Apr; 36(4):486-94. PubMed ID: 18249062 [TBL] [Abstract][Full Text] [Related]
33. Human Vγ9Vδ2 T cells specifically recognize and kill acute myeloid leukemic blasts. Gertner-Dardenne J; Castellano R; Mamessier E; Garbit S; Kochbati E; Etienne A; Charbonnier A; Collette Y; Vey N; Olive D J Immunol; 2012 May; 188(9):4701-8. PubMed ID: 22467661 [TBL] [Abstract][Full Text] [Related]
34. A novel HLA-A*0201 restricted peptide derived from cathepsin G is an effective immunotherapeutic target in acute myeloid leukemia. Zhang M; Sukhumalchandra P; Enyenihi AA; St John LS; Hunsucker SA; Mittendorf EA; Sergeeva A; Ruisaard K; Al-Atrache Z; Ropp PA; Jakher H; Rodriguez-Cruz T; Lizee G; Clise-Dwyer K; Lu S; Molldrem JJ; Glish GL; Armistead PM; Alatrash G Clin Cancer Res; 2013 Jan; 19(1):247-57. PubMed ID: 23147993 [TBL] [Abstract][Full Text] [Related]
35. A novel tetravalent bispecific antibody targeting programmed death 1 and tyrosine-protein kinase Met for treatment of gastric cancer. Hou W; Yuan Q; Yuan X; Wang Y; Mo W; Wang H; Yu M Invest New Drugs; 2019 Oct; 37(5):876-889. PubMed ID: 30511201 [TBL] [Abstract][Full Text] [Related]
36. Blockade of the PD-1/PD-L1 axis augments lysis of AML cells by the CD33/CD3 BiTE antibody construct AMG 330: reversing a T-cell-induced immune escape mechanism. Krupka C; Kufer P; Kischel R; Zugmaier G; Lichtenegger FS; Köhnke T; Vick B; Jeremias I; Metzeler KH; Altmann T; Schneider S; Fiegl M; Spiekermann K; Bauerle PA; Hiddemann W; Riethmüller G; Subklewe M Leukemia; 2016 Feb; 30(2):484-91. PubMed ID: 26239198 [TBL] [Abstract][Full Text] [Related]
37. Antibodies targeting human IL1RAP (IL1R3) show therapeutic effects in xenograft models of acute myeloid leukemia. Ågerstam H; Karlsson C; Hansen N; Sandén C; Askmyr M; von Palffy S; Högberg C; Rissler M; Wunderlich M; Juliusson G; Richter J; Sjöström K; Bhatia R; Mulloy JC; Järås M; Fioretos T Proc Natl Acad Sci U S A; 2015 Aug; 112(34):10786-91. PubMed ID: 26261316 [TBL] [Abstract][Full Text] [Related]
38. IL1RAP-specific T cell engager depletes acute myeloid leukemia stem cells. Zhang Y; Park M; Ghoda LY; Zhao D; Valerio M; Nafie E; Gonzalez A; Ly K; Parcutela B; Choi H; Gong X; Chen F; Harada K; Chen Z; Nguyen LXT; Pichiorri F; Chen J; Song J; Forman SJ; Amanam I; Zhang B; Jin J; Williams JC; Marcucci G J Hematol Oncol; 2024 Aug; 17(1):67. PubMed ID: 39143574 [TBL] [Abstract][Full Text] [Related]
39. CEA/CD3 bispecific antibody MEDI-565/AMG 211 activation of T cells and subsequent killing of human tumors is independent of mutations commonly found in colorectal adenocarcinomas. Oberst MD; Fuhrmann S; Mulgrew K; Amann M; Cheng L; Lutterbuese P; Richman L; Coats S; Baeuerle PA; Hammond SA MAbs; 2014; 6(6):1571-84. PubMed ID: 25484061 [TBL] [Abstract][Full Text] [Related]